Back to News
Market Impact: 0.15
Moderna Announces Late-Breaking Data to be Presented at ESMO Congress 2026
Source: Newswire
Healthcare & BiotechCorporate Guidance & Outlook
Moderna said Phase 3 data for intismeran autogene in adjuvant treatment of resected stage IIB-IV melanoma will be presented at a Presidential Symposium. The company will host a webcast investor event on October 24 at 7:00 PM CEST (1:00 PM EDT), but disclosed no efficacy, safety, or financial data.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.10
Ticker Sentiment
MRNA0.20
More News
- Moderna raises 2026 outlook as CEO says newer vaccines are gaining traction
- While biotech bets swing on trial data, this dividend payer gained 72% since 2024
- Tech stock rout, driven by US AI fears, continues in Asian trading
- RIP the Cybertruck: Elon Musk says Tesla will wind down production of its most polarizing EV
- Tesla will stop making the Cybertruck in 2027
- Tesla is 'winding down' Cybertruck production at its Texas Gigafactory